Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.5552W HIGH $2.41
Volume
204.20 K
Value Traded
327.18 K
Short % Float
0.24%
-6.01%Week
+13.47%1 Month
+0.92%3 Month
+14.06%6 Month
-93.81%5 Year
-96.27%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
121.26 M
EPS (TTM)
-1.23
P/E Ratio
-
Ent. Value
-88.22 M
Total Shares
55.37 M
Float Shares
36.95 M
Insiders
33.27%
Institutions
23.42%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SEER Catalyst Timeline
Dated clinical, regulatory and corporate events for Seer, Inc.
Past FDA Catalysts and PDUFA Decisions
How SEER actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Seer, Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every SEER program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Horn David R.Officer (PRESIDENT & CFO) | Sell | -7,309 486,650 held | $2.03 | 08/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SEER
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0.1 % | 2.92 M | 1.34 M |
SEER Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SEER ranks across every disease it competes in
Competitive Position is a premium feature
See how SEER ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSEER News
SEERSeer and Nanyang Technological University to Present Early Findings from Landmark PRECISE-SG100K Proteomics Study at HUPO 2026
Seer, Inc. announced that researchers from Nanyang Technological University will present early findings from the PRECISE-SG100K study at the HUPO World Congress 2026. This study aims to characterize the proteome of 10,000 participants in Singapore, integrating various biological data to enhance population health insights. The Proteograph Product Suite is utilized for deep proteomic analysis, potentially revealing important biomarkers and aiding precision medicine.
Read more →SEERSeer Announces CFO Transition
Seer, Inc. announced the departure of CFO David Horn, effective October 1, 2026, as he pursues a new opportunity. Charles Endweiss, currently VP of Financial Planning & Analysis, will take over as CFO. The leadership transition is expected to maintain the company's progress and success in the proteomics field.
Read more →SEERSeer Surpasses 100 Peer-Reviewed Customer Publications, Validating a New Era of Deep Proteomics at Scale
Seer, Inc. has announced that its Proteograph Product Suite has been utilized in over 100 peer-reviewed publications, marking a significant advancement in deep proteomics. This technology allows researchers to conduct deep, unbiased proteomic studies across large cohorts, overcoming previous limitations in the field. The findings span various areas including genetics, aging, and disease biology, highlighting the potential for future clinical applications.
Read more →SEERRadoff-JEC Group Calls on Meeta Gulyani to Immediately Resign from Seer, Inc.’s Board of Directors
Bradley L. Radoff and Michael Torok, significant shareholders of Seer, Inc., have publicly called for the resignation of board member Meeta Gulyani. They collectively own about 7.7% of the company's shares, indicating their influence and concern regarding the company's governance. The open letter highlights their dissatisfaction with the current board leadership.
Read more →SEERRadoff-JEC Group Calls on Seer, Inc.’s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers
Bradley L. Radoff and Michael Torok, shareholders of Seer, Inc., have urged the Board of Directors to recognize the necessity of taking the company private. They demand transparency regarding the timeline for assessing recent acquisition proposals. This call reflects growing shareholder concerns about the company's direction and governance.
Read more →SEERSeer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook
Seer, Inc. reported its financial results for the second quarter of 2026, achieving $3.1 million in revenue, a 23% decrease from the previous year. The company highlighted advancements in AI-driven plasma proteomics and maintained a strong patent position. Despite a net loss of $16.9 million, Seer reaffirmed its revenue guidance for the full year 2026, expecting growth over the previous year.
Read more →SEERSeer to Participate in the Canaccord Genuity 46th Annual Growth Conference
Seer, Inc. will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston, scheduled for August 12. The company's management will present from 8:00 a.m. to 8:25 a.m. Eastern Time. A live webcast will be available, along with an archived replay post-conference.
Read more →SEERSeer to Report Second Quarter 2026 Financial Results on August 11, 2026
Seer, Inc. announced it will report its financial results for the second quarter of 2026 on August 11, 2026. The company will host a conference call at 1:30 p.m. PT, which will be available via webcast. Seer is recognized for its advancements in deep proteomics, providing significant insights in the field.
Read more →SEER▲ +7.8%on this newsshared move
Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D.
Seer, Inc. has received two unsolicited acquisition proposals from the Radoff-JEC Group and its CEO, Omid Farokhzad. The Radoff-JEC Group proposed $2.55 per share, while Farokhzad offered $2.45 per share plus contingent rights. The company's Board will review these proposals and determine the best course of action for stockholders. No immediate action is required from stockholders.
Read more →SEERSeer Stockholders Vote to Re-Elect All Seven of Seer’s Director Nominees at 2026 Annual Meeting
Seer, Inc. announced that stockholders have voted to re-elect all seven director nominees during its 2026 Annual Meeting. The preliminary results indicate strong support for the Board, reflecting confidence in their commitment to the company's strategic goals. Seer aims to enhance its business operations and innovation pipeline while maintaining cost discipline.
Read more →SEER▲ +5.4%on this newsshared move
Radoff-JEC Group Submits Further Improved Proposal to Acquire Seer, Inc.
Bradley L. Radoff and Michael Torok, who own about 7.7% of Seer, Inc., have submitted an improved non-binding proposal to acquire the company for $2.55 per share in cash, along with a contingent value right. This marks their fourth proposal, reflecting ongoing interest in Seer's future.
Read more →SEER▼ -6%on this news
Seer Urges Stockholders to Vote “FOR” Seer’s Highly Qualified Director Nominees on the BLUE Proxy Card TODAY
Seer, Inc. is urging stockholders to vote for its qualified director nominees ahead of the 2026 Annual Meeting. The board emphasizes its commitment to long-term growth and strategic execution in the proteomics market. Concerns are raised about competing nominees lacking necessary qualifications, which could jeopardize the company's progress. Stockholders are encouraged to vote using the BLUE proxy card.
Read more →SEER▼ -6%on this news
Special Committee of Seer’s Board of Directors Unanimously Rejects Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.
Seer, Inc.'s Special Committee has unanimously rejected an unsolicited acquisition proposal from its CEO, Omid Farokhzad. The proposal, which offered $2.45 per share plus contingent value rights, was deemed insufficient to reflect Seer's growth potential. The Committee's decision was made after careful consideration and consultation with independent advisors.
Read more →SEERThe Radoff-JEC Group Urges Seer, Inc. Stockholders to Vote for Boardroom Change Today
The Radoff-JEC Group is calling on Seer, Inc. stockholders to support a change in the boardroom. However, the article provides minimal details about the motivations for this request or the implications of such a change. The lack of information may leave stockholders uncertain about the situation.
Read more →SEERThe Radoff-JEC Group Highlights Seer Inc.’s and Chairman and CEO Omid Farokhzad, M.D.’s History of Value Destruction
The article discusses the Radoff-JEC Group's focus on Seer Inc. and its leadership under Omid Farokhzad, M.D. It emphasizes a history of value destruction linked to the company, raising concerns about its management and strategic direction. The analysis suggests a critical view of the company's performance.
Read more →SEERSeer Board of Directors Issues Letter to Shareholders Highlighting the Company’s Significant Scientific Progress and Addressing Radoff and Torok’s Short-Sighted Campaign
Seer, Inc. has issued a letter to shareholders urging support for its board of directors ahead of the Annual Meeting on July 28, 2026. The letter highlights Seer's advancements in proteomics technology, significant growth in scientific validation, and disciplined financial management. The board recommends voting for its nominees against activist shareholders who propose undervalued acquisitions. The company emphasizes its commitment to long-term value creation.
Read more →SEERSeer Files Definitive Proxy Materials and Mails Letter to Stockholders
Seer, Inc. has filed definitive proxy materials for its upcoming Annual Meeting, urging stockholders to vote for its director nominees. The company emphasizes its strong governance and strategic direction while criticizing activist stockholders Radoff and Torok for their disruptive campaign. Seer highlights its progress in proteomics technology and the importance of maintaining its current board to ensure long-term value creation.
Read more →SEERSeer Files ITC Complaint Against Nanomics
Seer, Inc. has filed a complaint against Nanomics Biotechnology at the ITC, claiming patent infringement related to nanoparticle protein enrichment technologies. This action follows a federal district court lawsuit initiated earlier in May 2026. Seer aims to prevent the importation of Nanomics' products and protect its proprietary technology. The complaint is supported by Brigham and Women's Hospital.
Read more →SEERThe Radoff-JEC Group Calls on Seer Inc. and Its Advisors to Reevaluate Its Premium Acquisition Proposal in the Best Interests of All Stockholders
The Radoff-JEC Group has urged Seer Inc. and its advisors to reconsider their premium acquisition proposal. The group believes that the current proposal may not serve the best interests of all stockholders. This call for reevaluation highlights potential concerns regarding the adequacy of the offer.
Read more →SEERSeer to Showcase AI-Driven Multi-Cancer Screening Approach and Next-Generation Proteomics Capabilities at ASMS 2026
Seer, Inc. will showcase its AI-driven multi-cancer screening and next-generation proteomics at the ASMS 2026 conference. The company will present findings from collaborations, including a large-scale study analyzing over 20,000 clinical plasma samples. Seer aims to demonstrate the capabilities of its Proteograph platform in advancing biomarker discovery and precision medicine.
Read more →About Seer, Inc.
Headquarters3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY, CA, 94065
BIOPHARMAWATCH ELITE PLUS
Trade the next SEER catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime